Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Brequinar sodium

D V Cramer1

  • 1National Institute of Transplantation, St. Vincent Medical Center, Los Angeles, California, USA.

Transplantation Proceedings
|April 1, 1996
PubMed
Summary
This summary is machine-generated.

BQR shows promise for preventing graft rejection due to its immunosuppressive properties and bioavailability. However, its narrow therapeutic window, potentially due to a long plasma half-life, requires further investigation for safe human application.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subacute Study of Rats Fed Ground Beef Treated with Aqueous Chlorine - Anatomic Pathology.

Journal of food protection·2019
Same author

Specific and stable CTL tolerance induced by veto mechanism.

Immunology today·2014
Same author

Maturation of xenoantibody gene expression during the humoral immune response of rats to hamster xenografts.

Xenotransplantation·2001
Same author

Functional metabolic characteristics of intact pig livers during prolonged extracorporeal perfusion: potential for a unique biological liver-assist device.

Transplantation·2001
Same author

Dual cell seeding and the use of zymogen tissue plasminogen activator to improve cell retention on polytetrafluoroethylene grafts.

Journal of vascular surgery·2001
Same author

Characteristics of immunoglobulin gene usage of the xenoantibody binding to gal-alpha(1,3)gal target antigens in the gal knockout mouse.

Transplantation·2001
Same journal

Acute Rejection Mediated by Preformed Anti-HLA-C Antibody in a Kidney Transplant Patient: A Case Report.

Transplantation proceedings·2026
Same journal

Liver Transplantation for Metastatic Neuroendocrine Tumors: A Single-Center Experience in a Brazilian Referral Center.

Transplantation proceedings·2026
Same journal

Analysis of the Cost of Maintaining Effective Donors and Nondonors of Organs and Tissues in Intensive Care Units.

Transplantation proceedings·2026
Same journal

Adolescence and Pediatric Heart Transplantation: Impact of Non-Adherence on Mortality: A Single-Center Experience.

Transplantation proceedings·2026
Same journal

Impact of Family-Based Care on the Outcome of Brain Death and Humanization in the Process of Multiple Organ Donation: Case Report.

Transplantation proceedings·2026
Same journal

Karnofsky Performance Status Is Associated with Patient and Graft Survival After Liver Retransplantation.

Transplantation proceedings·2026
See all related articles

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Medicine

Background:

  • BQR demonstrates desirable characteristics for an antirejection protocol, including potent immunosuppression against allografts and xenografts.
  • Its efficacy is enhanced when combined with other immunosuppressants like CsA, offering a safe and effective strategy in rodent models.
  • High bioavailability, patient acceptance, and ease of monitoring plasma drug levels are additional advantages of BQR.

Purpose of the Study:

  • To evaluate the potential of BQR as a component in preventing graft rejection.
  • To explore the therapeutic benefits and limitations of BQR in immunosuppressive regimens.
  • To investigate strategies for optimizing BQR's therapeutic window and efficacy.

Main Methods:

  • Assessment of BQR's immunosuppressive activity as a single agent and in combination therapy.

Related Experiment Videos

  • Evaluation of BQR's pharmacokinetic profile, including bioavailability and plasma half-life.
  • Analysis of treatment schedules and their impact on graft survival and side effects in rodent models.

    • Main Results:

    • BQR effectively prevents graft rejection and inhibits antibody production.
    • Combination therapy with BQR and other agents like CsA shows enhanced immunosuppression in rodent models.
    • A narrow therapeutic window, possibly linked to BQR's extended plasma half-life, presents a challenge for human application.

    Conclusions:

    • BQR is a potent immunosuppressive agent with favorable pharmacokinetic properties, suitable for preventing graft rejection.
    • Optimizing BQR's therapeutic window, potentially by modifying its plasma half-life, is crucial for its clinical translation.
    • Further research, including biochemical modification of BQR, is warranted to enhance its safety and efficacy in human transplantation.